Detalhe da pesquisa
1.
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
N Engl J Med
; 389(22): 2039-2051, 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870976
2.
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
N Engl J Med
; 386(21): 1973-1985, 2022 05 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35403841
3.
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated EGFR Exon 20 insertion-mutated non-small-cell lung cancer.
Future Oncol
; 20(8): 447-458, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37882460
4.
Rapid and Highly Selective Fluorescent Labeling of Peptides via a Thia-Diels-Alder Cycloaddition: Application to Apelin.
Bioconjug Chem
; 34(1): 162-168, 2023 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36534753
5.
Molecular characterisation of tumours of the lacrimal apparatus.
Histopathology
; 83(6): 925-935, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37706251
6.
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy.
Acta Oncol
; 62(12): 1689-1697, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37938161
7.
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamab.
Future Oncol
; 19(33): 2213-2225, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37589131
8.
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
Future Oncol
; 19(8): 549-557, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815433
9.
Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer.
Int J Mol Sci
; 24(4)2023 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36835213
10.
Chest CT scan plus x-ray versus chest x-ray for the follow-up of completely resected non-small-cell lung cancer (IFCT-0302): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(9): 1180-1188, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35964621
11.
Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers.
Oncologist
; 27(11): 919-929, 2022 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35749302
12.
VTE with Amivantamab plus Chemotherapy in NSCLC. Reply.
N Engl J Med
; 390(6): 579-580, 2024 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38324503
13.
Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.
Cancer Immunol Immunother
; 71(7): 1719-1731, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34821950
14.
OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.
BMC Cancer
; 22(1): 41, 2022 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34991520
15.
New Strategies and Novel Combinations in EGFR TKI-Resistant Non-small Cell Lung Cancer.
Curr Treat Options Oncol
; 23(11): 1626-1644, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36242712
16.
CARMN-NOTCH2 fusion transcript drives high NOTCH2 expression in glomus tumors of the upper digestive tract.
Genes Chromosomes Cancer
; 60(11): 723-732, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34245196
17.
A multi-axial RNA joint with a large range of motion promotes sampling of an active ribozyme conformation.
Nucleic Acids Res
; 47(7): 3739-3751, 2019 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-30993347
18.
[Thymoma and squamous thymic carcinoma diagnosis; experience from the RYTHMIC network]. / Diagnostic des thymomes et carcinomes thymiques malpighiens ; expérience du réseau RYTHMIC.
Ann Pathol
; 41(2): 154-165, 2021 Apr.
Artigo
em Francês
| MEDLINE | ID: mdl-33309329
19.
Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer. Reply.
N Engl J Med
; 387(6): 572-573, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35947719
20.
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in EGFR-mutated non-small-cell lung cancer: a real life study.
Future Oncol
; 16(16): 1115-1124, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32352321